Zymeworks概述了收购Theravance后的指导方针

2026-09-28 18:51

Zymeworks (ZYME) Monday reported the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma.
The acquisition adds YUPELRI (revefenacin) to Zymeworks’ portfolio, providing a durable, recurring source of cash flow to fund the company’s long-term growth strategy, the company said.
Through Theravance Biopharma’s collaboration with Viatris, Zymeworks is entitled to a 35% share of net U.S. profits from YUPELRI and royalties on net sales outside the United States.
In the first half of 2026, total YUPELRI sales of $133.1 million resulted in collaboration revenue to Theravance Biopharma of $38.4 million.
Under the terms of the merger agreement reported on June 29, Theravance Biopharma shareholders received $17.00 in cash at closing for each share of Theravance Biopharma common stock.
The stock eased 1.2% premarket.

More on Zymeworks